Carbetocin: Physiology and What Research Reports

What Carbetocin Is

Carbetocin is a synthetic, long-acting analogue of oxytocin, the nine-amino-acid neuropeptide that mammals produce in the hypothalamus. Chemically it is a carba-analogue: the disulfide bridge of native oxytocin is replaced by a more stable carbon bridge, the first residue is deaminated, and a tyrosine residue is O-methylated. Those substitutions preserve the molecule's ability to activate the oxytocin receptor while making it less vulnerable to the enzymes and reductive chemistry that clear the native hormone quickly.

The important framing for a physiology library is that carbetocin is not endogenous. Nothing in the human body produces it. What the body does produce is oxytocin, and carbetocin is a laboratory-designed agonist that enters that same signalling pathway. Almost all of the clinical literature concerns its use as a uterotonic, where researchers have described its real-world application for prevention of postpartum haemorrhage after vaginal birth (PMID 34470143), alongside a smaller body of work on central, behavioural effects of oxytocin-receptor activation.

Where the Underlying Signal Comes From in the Body

Oxytocin is synthesised in magnocellular neurons of the paraventricular and supraoptic nuclei of the hypothalamus, transported along axons to the posterior pituitary, and released into the bloodstream; the same neurons also release peptide within the brain from dendrites and collateral projections. Peripherally, oxytocin reaches the oxytocin receptor (OXTR), a Gq-coupled G-protein-coupled receptor that is expressed densely on myometrial smooth muscle near term and on mammary myoepithelial cells. Receptor activation raises intracellular calcium and produces rhythmic uterine contraction and milk ejection. Centrally, OXTR is found in regions associated with social behaviour, appetite regulation, anxiety and reward.

This dual distribution explains the two very different research literatures around carbetocin. Uterine OXTR expression underlies its obstetric use; brain OXTR expression underlies experimental interest in feeding behaviour, distress and addiction-related phenotypes.

How Carbetocin Is Measured and Studied

Published work uses three broad approaches.

• Pharmacokinetic assays. A veterinary pharmacokinetic study measured plasma concentrations of carbetocin after intravenous and intramuscular administration in cows and gilts and reported bioavailability for the intramuscular route (PMID 31856330).
• Clinical outcome endpoints. Obstetric trials and cohorts track blood loss, need for additional uterotonic agents, transfusion and haemorrhage rates, as in a quasi-randomised phase IV non-inferiority trial that compared intramyometrial and intravenous oxytocin with intravenous carbetocin at elective caesarean section (PMID 38952085).
• Behavioural and biomarker readouts. Caregiver- and clinician-rated scales were used in Prader-Willi syndrome trials of intranasal carbetocin (PMID 36633570), while a rodent study used locomotor sensitisation and corticosterone measurement (PMID 37999545).

What the Obstetric Literature Reports

The largest cluster of carbetocin research asks whether a longer-acting oxytocin analogue performs comparably to oxytocin when given once for haemorrhage prophylaxis. Researchers conducted a quasi-randomised, phase IV non-inferiority trial comparing intramyometrial and intravenous oxytocin with intravenous carbetocin for prevention of postpartum haemorrhage in elective caesarean section (PMID 38952085). A before-after study compared carbetocin with oxytocin following both vaginal and caesarean delivery (PMID 34713434), and a retrospective cohort examined outcomes after an institutional policy change to carbetocin prophylaxis in all births (PMID 40890901). A separate report described how carbetocin was applied in routine practice for prevention of postpartum haemorrhage after vaginal birth (PMID 34470143).

Animal reproduction research has asked a parallel question. One study compared the effects of oxytocin and carbetocin on farrowing performance in sows (PMID 31047762), using the same receptor logic: a more stable agonist may sustain uterine activity differently from the native hormone.

Beyond the Uterus: Central and Behavioural Research

Because oxytocin receptors are expressed in appetite- and stress-related brain circuits, carbetocin has been investigated as an intranasal agent in Prader-Willi syndrome. An early study reported that intranasal carbetocin reduced hyperphagia in individuals with Prader-Willi syndrome (PMID 29925684), and the subsequent CARE-PWS phase 3 trial reported reductions in hyperphagia, anxiousness and distress with intranasal carbetocin (PMID 36633570). In preclinical work, researchers reported that carbetocin inhibited behavioural sensitisation to ethanol in male and female mice, and that this occurred independently of corticosterone levels (PMID 37999545).

Carbetocin Tolerability: What Studies Report

Safety questions in the published literature follow the receptor's distribution. Oxytocin-receptor agonists act on vascular and possibly cardiac tissue, so a double-blind randomised controlled trial measured troponin release as well as postpartum haemorrhage in participants given prophylactic oxytocin or carbetocin at planned caesarean delivery (PMID 40772429). Comparative tolerability was also part of the before-after evaluation of carbetocin versus oxytocin after vaginal and caesarean delivery (PMID 34713434). In the central-nervous-system setting, the CARE-PWS phase 3 trial reported safety and tolerability findings alongside its behavioural endpoints for intranasal carbetocin (PMID 36633570). Readers comparing agents should note that adverse-event profiles reported in one route and population do not transfer automatically to another.

Cost and Health-System Questions

Carbetocin is unusual among peptides in that its literature includes explicit economic analysis. A review examined whether the agent is "worth the extra expense" relative to oxytocin (PMID 31164260), and a formal cost-effectiveness analysis compared carbetocin with oxytocin for prevention of postpartum haemorrhage following vaginal birth in the United Kingdom (PMID 35007465). Storage stability, single-dose administration and avoidance of infusion pumps are the practical variables such analyses weigh.

Why the Term Matters to Peptide Readers

Carbetocin is a useful case study in peptide pharmacology. It shows how small structural edits to a natural nonapeptide, such as replacing a disulfide bridge, can change stability and duration of action, a point that the pharmacokinetic work in cows and gilts illustrated with intravenous and intramuscular comparisons (PMID 31856330). It also illustrates that a single receptor can support entirely separate clinical literatures, obstetric and neurobehavioural, studied by different routes of administration. Carbetocin is a prescription medicine in the jurisdictions where it is licensed; it is not a general-wellness compound, and the trials summarised here were conducted in tightly defined clinical populations under medical supervision. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or symptom.

References

• Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial (The Journal of Clinical Endocrinology and Metabolism, 2023)
• Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome (JCI Insight, 2018)
• Effects of oxytocin and carbetocin on farrowing performance (Animal Reproduction Science, 2019)
• Carbetocin for the prevention of post-partum hemorrhage after vaginal birth: a real-world application (The Journal of Maternal-Fetal & Neonatal Medicine, 2022)
• Carbetocin for Postpartum Haemorrhage Prophylaxis in All Births: A Retrospective Cohort Study Following Policy Change in Routine Uterotonic Use (BJOG, 2026)
• Effects of Prophylactic Oxytocin or Carbetocin on Troponin Release and Postpartum Haemorrhage at Planned Caesarean Delivery: A Double-Blind Randomised Controlled Trial (BJOG, 2025)
• Carbetocin Inhibits Behavioral Sensitization to Ethanol in Male and Female Mice, Independent of Corticosterone Levels (Toxics, 2023)
• Pharmacokinetics and bioavailability of carbetocin after intravenous and intramuscular administration in cows and gilts (Journal of Veterinary Pharmacology and Therapeutics, 2020)
• Intramyometrial and intravenous oxytocin compared to intravenous carbetocin for prevention of postpartum hemorrhage in elective cesarean section (Acta Obstetricia et Gynecologica Scandinavica, 2024)
• Carbetocin: Worth the extra expense? (Best Practice & Research: Clinical Obstetrics & Gynaecology, 2019)
• Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom (Journal of Medical Economics, 2022)
• Carbetocin versus oxytocin following vaginal and Cesarean delivery: a before-after study (Canadian Journal of Anaesthesia, 2022)